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Background: Post-transplant diabetes mellitus (PTDM) has been associated with an increased risk of cardiovascular
disease (CVD) mortality following kidney transplantation, but the association between pre-diabetes (i.e. impaired
fasting glucose and impaired glucose tolerance) and CVD mortality remains unclear. The aim of this study was to
assess the association between abnormal glucose regulation and arterial stiffness at 3 and 15 months
post-transplantation.
Methods: This is a single-centre prospective cohort study of 83 non-diabetic kidney transplant recipients who received
a kidney transplant between 2008 and 2011. All patients underwent an oral glucose tolerance test (OGTT – categorised
as normal, pre-diabetes or PTDM) and non-invasive measurements of arterial stiffness (aortic pulse wave velocity [PWV]
and augmentation index [AIx]) 3 months post-transplantation. A sub-set of patients had repeat OGTT (n = 33) and
arterial stiffness measurements (n = 28) at 15 months post-transplant.
Results: Of the 83 patients, 52% (n = 43) had normal glucose regulation, 31% (n = 26) had pre-diabetes and 17%
(n = 14) developed PTDM. Compared with recipients with normal glucose regulation, recipients with PTDM (adjusted
β = 5.61, 95% confidence interval [CI] 0.09 to 11.13, p = 0.047) but not those with pre-diabetes (adjusted β = 3.23, 95%
CI -1.05 to 7.51, p = 0.137) had significantly higher AIx 3 months after transplantation. No association was found between
glucose regulation and PWV at 3 months after transplantation. There was no association between glucose regulation at 3
or 15 months and AIx and PWV at 15 months in a subset of recipients.
Conclusions: Early onset PTDM is associated with increased systemic vascular stiffness (AIx) but not regional stiffness of
large arteries (PWV) suggesting that small vessel dysfunction may be the earliest vascular change seen with PTDM. Thus,
measurements of arterial stiffness after transplantation may assist in more accurately stratifying future CVD risk of kidney
transplant recipients.
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Augmentation index, Aortic pulse wave velocityIntroduction
Cardiovascular disease (CVD) remains one of the leading
causes of death with functioning graft in kidney transplant
recipients [1-3]. The development of metabolic and vascu-
lar complications such as post-transplant diabetes mellitus
(PTDM), hypertension and dyslipidaemia has contributed
to the increased risk of CVD in this population [4,5].* Correspondence: andrea.viecelli@health.wa.gov.au
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unless otherwise stated.Abnormal glucose regulation including PTDM and pre-
diabetes (impaired fasting glucose [IFG] and/or impaired
glucose tolerance [IGT]) is a common complication in
non-diabetic renal transplant recipients and is present in
48 to 54% of patients at 10 weeks following kidney trans-
plantation [6,7]. However, it has been shown that glucose
regulation following transplantation is a dynamic process,
with the incidence of PTDM and IGT declining from 54%
at 10 weeks to 35% at 6 years, likely related to reduction in
immunosuppression [7]. Multiple risk factors predispose toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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kidney transplantation, including the use of calcineurin-
inhibitors (CNI) and corticosteroids [8]. Compared to
kidney transplant recipients with normal glucose regu-
lation, early development of PTDM at 3 months after
transplantation is associated with a 3-fold higher risk of
major CVD events post-transplant, similar to that of re-
cipients with pre-transplant diabetes [5]. However, it re-
mains unclear whether pre-diabetes after transplantation
is associated with a similarly high risk of CVD events.
Non-invasive measurements of arterial stiffness and
wave reflection such as aortic augmentation index (AIx)
and pulse wave velocity (PWV) are established surrogate
markers of CVD mortality in the general population
[9-15], patients with hypertension [16], diabetes [17],
chronic kidney disease patients [18,19] and in kidney
transplant recipients [20,21]. In kidney transplant recipi-
ents, these measurements have been shown to improve
CVD risk stratification, which is crucial in the long-term
management of these patients [20].
The aim of this prospective cohort study of non-
diabetic kidney transplant recipients is to examine the
associations between abnormal glucose regulation at
3 months after kidney transplantation and arterial stiff-




This single-centre, prospective cohort study included all
incident non-diabetic live and deceased donor kidney
transplant recipients (n = 83) at Sir Charles Gairdner
Hospital (Perth, Australia) between January 2008 and
January 2011. All recipients had normal fasting and ran-
dom blood glucose levels prior to transplantation. The
local institutional ethics committee approved the study
and written informed consents were obtained from all
patients.
Patient characteristics (age, gender), medical history
(prevalent CVD, hypertension, cause of end-stage renal dis-
ease, pre-transplant dialysis modality and dialysis duration)
and kidney transplant-related characteristics (donor age
and type, immunological risk) were extracted from medical
records. Medications including immunosuppressive, anti-
hypertensive and lipid-lowering agents at 3 months (base-
line) and 15 months were recorded.
Immunosuppression protocol
All kidney transplant recipients received induction ther-
apy with an anti-interleukin-2 receptor antibody (basilix-
imab, day 0 and 4 post-transplant) and were maintained
on CNI (cyclosporin or tacrolimus), mycophenolic acid
(MPA, mycophenolate mofetil or enteric coated myco-
phenolate sodium) and corticosteroids. The dose of CNIwas adjusted to achieve target therapeutic levels as per
local clinical practice. Recipients received two doses
of intravenous methylprednisolone (day 0 and 1 post-
transplant) and were then maintained on a tapering
dose of prednisolone, reaching 10 mg daily by 3 months
post-transplant. Indication and 3-month protocol biop-
sies were performed and management of acute rejection
with intravenous methylprednisolone was according to
standard local clinical practice (1 gram over 3 days).
Data collection
At 3 months after transplantation, height and weight (to
calculate body mass index [BMI]), blood pressure (average
of three readings), Modification Diet of Renal Disease
(MDRD)-derived estimated glomerular filtration rate (eGFR)
[22], urine protein to creatinine ratio (uPCR), haemato-
logical and other biochemical parameters were recorded.
An oral glucose tolerance test (OGTT) was performed
at 3 months in all kidney transplant recipients. This test
was undertaken following an overnight 8-hour fast and
venous blood samples for blood glucose (at 0, 1 and
2 hours) and fasting insulin were taken following admin-
istration of 75 g oral glucose load. Recipients were clas-
sified as having normal glucose regulation, pre-diabetes
(IFG and/or IGT) or PTDM in accordance with the
American Diabetes Association guidelines [23]: IFG was
defined by fasting plasma glucose of ≥ 5.6 mmol/L and <
7.0 mmol/L, IGT defined by 2-hour plasma glucose of ≥
7.8 mmol/L and < 11.1 mmol/L and PTDM defined by fast-
ing plasma glucose of ≥ 7.0 mmol/L or 2-hour plasma glu-
cose of ≥ 11.1 mmol/L. Normal glucose regulation was
defined by fasting plasma glucose of < 5.6 mmol/L and 2-
hour plasma glucose of < 7.8 mmol/L. Insulin resistance
and beta cell function were assessed using the Homeostasis
Model Assessment Insulin Resistance (HOMA-IR) score
[fasting insulin (mU/mL) × fasting glucose (mmol/L)/22.5]
and HOMA-% beta score [fasting insulin (mU/mL) × 20/
{fasting glucose (mmol/L) – 3.5}] [24].
Arterial stiffness
Arterial stiffness and wave reflections were measured non-
invasively following an overnight 8-hour fast by applana-
tion tonometry at 3 months post-transplantation using
SphygmoCor® (North Ryde, Sydney, Australia). A single
operator conducted the measurements with coefficient
variation of <10%. Aortic PWV (reflecting regional stiff-
ness of large arteries) was measured as the carotid-femoral
PWV using the foot-to-foot method (average of two mea-
surements) [25]. AIx adjusted for heart rate (reflecting sys-
temic vascular stiffness) was measured from the radial
artery and a validated transfer function was used to derive
this measurement. An average of three consecutive read-
ings, each consisting of at least 20 sequentially recorded
waveforms, was captured for analysis.
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In a subset of kidney transplant recipients, a repeat OGTT
(n = 33) and measurements of arterial stiffness and wave
reflections (n = 28) were obtained at 15 months after
transplantation. Clinical history (up to 15 months post-
transplantation), BMI, blood pressure, MDRD-derived
eGFR, uPCR, haematological and biochemical parameters
were also obtained for this time-point.
Characteristics of those kidney transplant recipients who
were lost to follow-up at 15 months post-transplant were
similar compared to those with 15-month data: There were
no significant differences in recipient (age, gender, time on
dialysis) and donor (age and donor type) characteristics,
transplant (immunological matching or mean drug dose/
levels including prednisolone dose, cyclosporin and tacroli-
mus levels, graft function and rejection rates) or vascular
(AIx, PWV, blood pressures) outcomes.
Statistical analysis
Results are presented as frequency (percentage) for cat-
egorical variables or as mean and standard deviation
(SD) for continuous variables. Comparisons of baseline
characteristics between the three groups (normal glucose
regulation, pre-diabetes and PTDM) were made by chi-
square test for categorical variables and one-way analysis
of variance (ANOVA) for continuous variables. Associa-
tions between glucose regulation at 3 and 15-months
and 3 and 15-months PWV and AIx were examined
using unadjusted and adjusted linear regression. In the
adjusted model, only covariates with p-value of < 0.2 in
the unadjusted models were included. To detect a 20%
difference in AIx between kidney transplant recipients
with normal glucose regulation and pre-diabetes, a sam-
ple size of 25 per group was required assuming an alpha
of 5%, power of 80% and SD of 7%. Statistical evaluation
was performed by SPSS version 10 statistical software
program (SPSS, North Sydney, Australia). A p-value of
less than 0.05 was considered statistically significant.
Results
Baseline characteristics
Of the 83 kidney transplant recipients, 43 (52%) had nor-
mal glucose regulation, 26 (31%) had pre-diabetes and 14
(17%) developed PTDM at 3 months after transplantation.
Table 1 shows the donor, recipient and transplant-related
characteristics as categorised by glucose regulation at
3 months post-transplant. All recipients were of Caucasian
ethnicity. There were no significant differences in donor
and recipient age, BMI, prevalent hypertension or CVD be-
tween the three groups. There was a mean reduction in
BMI between pre-transplant and 3 months post-transplant
in those who developed PTDM and pre-diabetes (mean
change in BMI -0.19 kg/m2 and -0.16 kg/m2, respectively)
compared to those with normal glucose regulation(+0.20 kg/m2, p = 0.039). The proportion of live-donor kid-
ney transplants was similar (normal glucose regulation
48.8%, pre-diabetes 57.7% and PTDM 35.7%, χ2 p = 0.41).
There was no significant difference in the proportion of re-
cipients maintained on tacrolimus or cyclosporin or CNI
drug levels.
Graft outcome at 3 months
At 3 months, graft and patient survivals were 100%. All re-
jection episodes (n = 4) occurred beyond 3 months post-
transplant, at least 1 month after the 3-month OGTT. The
proportion of recipients who experienced biopsy-proven
acute rejection was not significantly different between
groups (4.7%, 7.7%, and 0.0% in recipients with normal glu-
cose regulation, pre-diabetes and PTDM respectively, χ2
p = 0.55). There was no significant difference in tacrolimus
and cyclosporin drug levels and CNI type in those with and
without rejection. Similarly, mean eGFR and uPCR were
not statistically different between groups (Table 1).
Biochemical parameters at 3 months
There were no significant differences in cholesterol or
triglyceride levels although more recipients with PTDM
were prescribed a statin (78.6% of recipients with PTDM
as compared to 46.2% and 34.9% of patients with pre-
diabetes and normal glucose regulation, respectively; χ2
p = 0.02). Mean ± SD HOMA-IR scores were similar be-
tween groups (normal: 1.83 ± 1.11, pre-diabetes: 1.85 ±
0.71, PTDM: 2.48 ± 1.25; 1-way ANOVA p = 0.26).
Serum calcium and phosphate levels were comparable
between the three glucose regulation groups.
Arterial stiffness at three months
At 3 months post-transplant, recipients with PTDM had
significantly higher mean ± SD AIx (26.4 ± 6.7%) com-
pared with those with pre-diabetes (22.9 ± 6.8%) and
normal glucose regulation (19.1 ± 11.6%, p-value for
trend 0.04). PWV, systolic and diastolic blood pressures
were similar across the three groups. The number and
type of anti-hypertensive medications including the use
of beta-blockers, calcium channel blockers, angiotensin
II receptor blockers and angiotensin-converting enzyme
inhibitors were comparable between the three groups.
Association between glucose regulation and arterial
stiffness at 3 months
Compared with recipients with normal glucose regulation,
recipients with PTDM had significantly higher AIx in both
the unadjusted (β coefficient 7.33, 95% CI 1.43 to 13.23,
p = 0.015) and adjusted linear regression models (β coeffi-
cient 5.61, 95% CI 0.09 to 11.13, p = 0.047). In contrast, re-
cipients with pre-diabetes had similar AIx compared to
recipients with normal glucose regulation (adjusted β coef-
ficient 3.23, 95% CI -1.05 to 7.51, p = 0.137). There was no
Table 1 3-month parameter including donor- and recipient characteristics as well as graft, cardiovascular and
metabolic outcomes
NGR (n = 43) IFG/IGT (n = 26) PTDM (n = 14) P-value*
Donor characteristics
Live donor, % 48.8 57.7 35.7 0.41
Age in years, mean (SD) 46.8 (16.8) 51.0 (12.4) 53.3 (12.0) 0.29
Recipient characteristics
Age in years, mean (SD) 49.5 (14.0) 54.2 (11.4) 51.1 (8.0) 0.27
Male, % 30.2 38.5 64.3 0.08
Body mass index in kg/m2, mean (SD) 27.2 (5.2) 26.7 (4.0) 25.1 (3.9) 0.60
Time on dialysis in years, mean (SD) 2.9 (2.8) 2.9 (3.3) 2.1 (2.3) 0.67










HLA mismatch out of 6, mean (SD) 3.0 (1.7) 3.7 (1.5) 3.4 (1.4) 0.21
Peak PRA, % 21.9 9.9 31.6 0.12
Prevalent hypertension, % 30 25 34 0.88
Prevalent cardiovascular disease, % 5 10 8 0.52
Immunosuppression
Tacrolimus, % 70 46 71 0.18
Steroid dose in mg/d, mean (SD) 10.2 (2.2) 9.2 (1.7) 9.6 (0.9) 0.10
Graft outcomes
eGFR in ml/min/1.73 m2, mean (SD) 52.2 (17.1) 51.0 (20.3) 48.0 (16.6) 0.75
Acute rejection, %** 4.7 7.7 0.0 0.55
Spot urine protein/creatinine ratio in mg/g, mean (SD) 20.1 (22.0) 55.2 (83.0) 62.1 (87.1) 0.23
Cardiovascular outcomes
Βeta-blocker, % 37.2 50.0 42.9 0.58
ACE-I, % 23.3 38.5 35.7 0.36
ARB, % 11.6 15.4 21.4 0.65
Calcium channel blockers, % 23.3 38.5 42.9 0.25
Number of antihypertensive agents, mean (SD) 1.0 (0.9) 1.4 (0.9) 1.4 (0.9) 0.16
Statin, % 34.9 46.2 78.6 0.02
Aspirin, % 18.6 19.2 35.7 0.37
Systolic BP in mmHg, mean (SD) 141.1 (16.0) 139.0 (14.8) 132.7 (12.8) 0.20
Diastolic BP in mmHg, mean (SD) 77.6 (13.9) 80.4 (7.5) 79 (8.8) 0.62
AIx in %, mean (SD) 19.1 (11.6) 22.9 (6.8) 26.4 (6.7) 0.04
Aortic PWV in m/s, mean (SD) 7.1 (1.6) 7.9 (2.4) 7.8 (2.3) 0.21
Metabolic outcomes
Cholesterol in mg/dl (SD) 5.2 (1.7) 5.7 (1.0) 4.6 (0.9) 0.07
Triglyceride in mg/dl (SD) 2.3 (2.3) 2.2 (0.9) 2.0 (0.5) 0.90
HOMA-IR, mean (SD) 1.83 (1.11) 1.85 (0.71) 2.48 (1.25) 0.26
HOMA-% beta, mean (SD) 0.03 (0.2) 0.03 (0.01) 0.03 (0.01) 0.35
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Table 1 3-month parameter including donor- and recipient characteristics as well as graft, cardiovascular and
metabolic outcomes (Continued)
Albumin-adjusted Calcium in mmol/l, mean (SD) 2.5 (0.1) 2.6 (0.2) 2.5 (0.2) 0.08
Phosphate in mmol/l, mean (SD) 0.90 (0.23) 0.79 (0.18) 0.80 (0.26) 0.12
Hemoglobin in g/l, mean (SD) 122 (19) 119 (15) 114 (18) 0.34
Abbreviations: ACE-I Angiotensin-converting enzyme inhibitor, AIx Augmentation index corrected for heart rate, ARB Angiotensin receptor blocker, BP Blood
pressure, CI Confidence interval, eGFR Estimated glomerular filtration rate, HLA Human leukocyte antibody, HOMA-%beta Homeostatic model assessment beta cell
function, HOMA-IR Homeostatic model assessment insulin resistance, IFG Impaired fasting glucose, IGT Impaired glucose tolerance, PTDM Post-transplant diabetes
mellitus, PRA Panel reactive antibody, PWV Pulse wave velocity. *Comparison between groups using chi square test for categorical variables and
one-way analysis of variance for continuous variables. **All rejection episodes occurred beyond 3 months post-transplant.
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the unadjusted and adjusted models (Table 2). There was
no association between cyclosporin and tacrolimus levels or
CNI type and PWV or AIx in the unadjusted linear regres-
sion model (i.e. p > 0.2).
Longitudinal sub-study
In a subset of 28 kidney transplant recipients, mean ± SD
AIx and PWV at 15 months were not significantly different
between groups (PTDM: 26.8 ± 9.6% and 7.9 ± 1.5 m/s re-
spectively; pre-diabetes: 25.6 ± 6.8% and 8.6 ± 1.9 m/s re-
spectively; normal glucose regulation: 22.1 ± 8.6% and 7.0 ±
1.9 m/s respectively, p = 0.458 and p = 0.152 respectively;
Figure 1). Repeat OGTT testing at 15 months in 33 kidney
transplant recipients showed that the proportion of recipi-
ents with normal glucose regulation increased from 52% at
3 months to 64% at 15 months and this improvement was
attributed primarily to a decrease in the proportion of pre-
diabetic patients from 31% at 3 months to 21% at 15 months,
whereas the proportion of patients with PTDM remained
similar (17% at 3 months and 15% at 15 months). There
was no association between glucose regulation at 3 months
and AIx and PWV at 15 months in the unadjusted (AIx:
normal glucose regulation = referent; pre-diabetes: β coeffi-
cient 2.19, 95% CI -4.68 to 9.06, p= 0.518; PTDM: β coeffi-
cient 3.32, 95% CI -5.02 to 11.66, p= 0.420 and PWV:
normal glucose regulation = referent; pre-diabetes: β coeffi-
cient 1.33, 95% CI -0.20 to 2.85, p = 0.09; PTDM: β coeffi-
cient 0.28, 95% CI -1.68 to 2.24, p= 0.771) and adjustedTable 2 Association between glucose regulation and AIx and
Covariates AIx, β coefficient (95%
PTDM compared to NGR 5.61 (0.09 to 11.13; p
IFG/IGT compared to NGR 3.23 (-1.05 to 7.51; p
Recipient age 0.19 (0.03 to 0.34; p
Recipient male gender -7.68 (-11.64 to -3.72;
Donor type (live vs. deceased) 3.09 (-0.67 to 6.84; p
Donor age -0.12 (10.25 to 0.003;
Systolic BP 0.11 (-0.02 to 0.23; p
Adjusted linear regression, data expressed as non-standardized regression coefficie
Abbreviations: BP Blood pressure, IFG Impaired fasting glucose, IGT Impaired glucose
velocity, NGR Normal glucose regulation, PTDM Post-transplant diabetes mellitus.models (AIx: normal glucose regulation = referent; pre-
diabetes: β coefficient 1.12, 95% CI -3.45 to 8.56, p= 0.455;
PTDM: β coefficient 1.56, 95% CI -4.50 to 9.42, p = 0.688
and PWV: normal glucose regulation = referent; pre-
diabetes: β coefficient 0.79, 95% CI -0.40 to 3.11, p= 0.431;
PTDM: β coefficient 0.11, 95% CI -1.57 to 2.59, p= 0.870).
There was no association between glucose regulation at
15 months and AIx and PWV at 15 months in both the un-
adjusted and adjusted models.
Between 3 and 15 months post-transplant, there was a
reduction in the mean dose of oral prednisolone (from
9.8 mg daily [range 5 to 15.5 mg] to 6.4 mg daily [range
2.5 - 10.0 mg]) and the proportion of recipients main-
tained on tacrolimus (70% to 58%). The change in CNI
type was directed by each patient’s physician and specific
reasons were not collected. As per standard local prac-
tice, therapeutic levels of CNI were lower at 15 months
compared to 3 months post-transplant.
Discussion
This study has shown that early development of PTDM
but not pre-diabetes at 3 months following kidney trans-
plantation is associated with increased AIx as compared
to those with normal glucose regulation, independent of
traditional CVD risk factors such as age, eGFR and gen-
der. However, there was no association between glucose
regulation and aortic PWV. In a sub-study, we have also
shown that glucose regulation post-transplantation is a
dynamic process with over 10% of recipients normalizingaortic PWV at 3 months post-kidney transplant
CI; p value) PWV, β coefficient (95% CI; p value)
= 0.047) 7.25 (-10.10 to 24.60; p = 0.404)
= 0.137) 7.15 (-7.27 to 21.57; p = 0.323)
= 0.01) -0.36 (-0.89 to 0.17; p = 0.181)
p < 0.01) 8.62 (-4.47 to 21.71; p = 0.191)
= 0.105) 8.38 (-4.87 to 21.62; p = 0.209)
p = 0.056) -0.02 (-0.54 to 0.50; p = 0.948)
= 0.095) 0.63 (0.14 to 1.12; p = 0.014)
nt (β coefficient) with 95% confidence interval (CI).


























Figure 1 Mean AIx (%) and aortic PWV (m/s) at 3 and 15 months post-kidney transplant. Abbreviations: AIx Augmentation index corrected
for heart rate, IFG Impaired fasting glucose, IGT Impaired glucose tolerance, NGR Normal glucose regulation, PTDM Post-transplant diabetes mellitus,
PWV, Pulse wave velocity.
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post-transplant, predominantly in those with pre-diabetes
at 3 months post-transplant.
This is the first prospective study that has evaluated
the association between early development of abnormal
glucose regulation after kidney transplantation and ar-
terial stiffness and wave reflections. A study of 79 kid-
ney transplant recipients maintained on CNI, MPA and
corticosteroids demonstrated that recipients with
PTDM (n = 11) had significantly higher brachial-ankle
PWV (1.59 ± 0.34 m/s) compared to recipients without
PTDM (1.34 ± 0.21 m/s, p < 0.01) [26]. Unlike our study,
diagnosis of PTDM and measurements of PWV were
delayed until at least 3 years after kidney transplant-
ation, which may have contributed to the differences in
findings. Structural changes in large blood vessels (lead-
ing to increased PWV) may occur only after prolonged
exposure to hyperglycaemia and therefore these changes
may not be readily observed in recipients who have de-
veloped early PTDM. In addition, unlike aortic PWV,
vascular stiffness in this study was assessed by brachial-
ankle PWV, which reflects both central and peripheral
arterial stiffness and has less robust evidence than aortic
PWV as surrogate marker of CVD mortality [27].
Non-invasive measurements of arterial stiffness and
wave reflections are established surrogate markers of CVD
and all-cause mortality. Carotid-femoral (aortic) PWV is a
reliable measurement of central arterial stiffness; whereas
AIx is a measurement of systemic arterial stiffness, which
reflects both elastic and muscular arterial stiffness and
wave reflections [25,27]. Elevated carotid-femoral PWV
has been shown to be associated with at least a 1.2-fold in-
creased risk of CVD morbidity and/or mortality in the
general population [9-13], patients with comorbidities in-
cluding hypertension [14-16,28] and diabetes [18] and in
patients with ESRD, including those on maintenance dia-
lysis and kidney transplant recipients [19,20,29]. Similarly,
there is a strong association between AIx and CVD eventsin patients with ESRD [21]. In a prospective study of
512 kidney transplant recipients with a mean follow-up
of 5 years post-transplant, every 1 SD increase in
carotid-femoral PWV (2.7 m/s) and central augmenta-
tion pressure (8.6 mmHg) was associated with a 35%
(p = 0.003) and 49% (p < 0.001) increased risk of non-
fatal and fatal CVD events respectively, independent of
other CVD risk factors. The inclusion of PWV and cen-
tral augmentation pressure to the European SCORE sys-
tem, the equivalent of the Framingham Risk Score for
CVD mortality, significantly improved CVD risk reclas-
sification by almost 16% [20].
Our study has shown that early development of PTDM
at 3 months post-transplantation was associated with
higher systemic (AIx) but not central arterial stiffness (aor-
tic PWV), suggesting that small vessel dysfunction may be
the earliest detectable vascular damage in those with early
PTDM. Longer follow-up of recipients with PTDM may
be required to detect changes in large vessel arterial stiff-
ness (PWV). Two general population-based cohorts total-
ing 5685 individuals demonstrated that arterial stiffness
increases and arterial compliance decreases significantly
with increasing severity of abnormal glucose regulation,
with patients with PTDM and pre-diabetes having a 17%/
10% and 10%/5% respectively higher brachial-ankle PWV/
lower total systemic arterial compliance compared to
those with normal glucose regulation [30-32]. Unlike these
studies, we did not demonstrate an association between
pre-diabetes and arterial stiffness. Differences in subjects’
characteristics (general population with no chronic kidney
disease vs. kidney transplant recipients), number of sub-
jects with pre-diabetes (170 to 726 vs. 26) and measure-
ments of arterial stiffness (brachial-ankle PWV and arterial
compliance vs. AIx and carotid-femoral PWV) are likely to
have contributed to dissimilar findings. The pathogenesis of
hyperglycaemia-induced damage to blood vessel walls re-
mains poorly understood. Activation of pro-inflammatory
transcription factors (such as nuclear factor κB), promotion
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of advanced glycation end-products have been shown to
alter the key matrix molecules of blood vessel wall, result-
ing in build-up of inelastic matrix material similar to that of
the effect of aging on blood vessel walls [27,33,34]. It re-
mains unclear whether similar blood vessel wall changes
occur in kidney transplant recipients who develop abnor-
mal glucose regulation and whether these changes are po-
tentially reversible with early recognition and appropriate
treatments.
Glucose regulation after kidney transplantation appears
to be a dynamic process. In our study, up to 30% of kidney
transplant recipients with pre-diabetes at 3 months nor-
malized their abnormal glucose regulation at 15-months
post-transplant, likely related to overall reduction in im-
munosuppression such as corticosteroids and CNI, agents
known to induce insulin resistance and/or beta cell dys-
function [35]. Similarly, a previous study of 95 kidney
transplant recipients showed that 50% of recipients
with pre-diabetes diagnosed by OGTT at 6 weeks post-
transplant had a normal OGTT at 6 years post-transplant,
presumably related to a reduction in immunosuppression
[7]. However, the effect of changing glucose regulation on
arterial stiffness and CVD events remains unknown and
longitudinal study evaluating kidney transplant recipients
with and without persistent abnormal glucose regulation
is required.
The strength of this study is the completeness of data in
our cohort and the availability of longer-term data in a
subset of kidney transplant recipients. Our study is limited
by the lack of pre-transplant measurements of arterial
stiffness and wave reflections (potential for unidentified
confounders) and the relatively small numbers (type II
error) which may explain the absence of an association be-
tween arterial stiffness and abnormal glucose regulation in
our sub-study analysis. As with any single-centre study,
the generalizability of our findings to other population
groups may be limited. Even though all kidney transplant
recipients had normal fasting and random blood glucose
levels prior to transplantation, the unavailability of pre-
transplant OGTT may potentially have led to inclusion of
recipients with unrecognized pre-transplant diabetes or
pre-diabetes.
Conclusions
At three months following kidney transplantation,
PTDM is associated with small vessel dysfunction (AIx),
an established predictor of CVD mortality. Measure-
ments of arterial stiffness after transplantation may help
to more accurately stratify the future risk of CVD mor-
tality in kidney transplant recipients. Larger longitu-
dinal studies examining the association between glucose
regulation, arterial stiffness and hard CVD clinical end-
points in kidney transplant recipients are required priorto considering whether interventional clinical trials in
those with early abnormal glucose regulation could re-
duce the risk of future CVD events.
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